September 26th 2023
Abeona Therapeutics is seeking Priority Review and approval of the therapy for patients with recessive dystrophic epidermolysis bullosa.
September 12th 2023
The IL-17A inhibitor did not meet its phase 2b/3 clinical trial primary end point.
The submission follows the announcement of recent long-term data of the drug in patients ages 6 years and older.
August 1st 2023
Both companies are hoping to make a positive impact in the neoadjuvant setting of cutaneous squamous cell carcinoma.
July 27th 2023
V940-001 is the first phase 3 study of a planned comprehensive clinical development program initiated after the positive primary analysis of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial.
FDA approves Aleor’s adapalene gel for acne vulgaris
The U.S. Food and Drug Administration has approved the Abbreviated New Drug Application for topical retinoid adapalene gel USP, 0.3% from Alembic Pharmaceuticals and its joint venture Aleor Dermaceuticals for treatment of acne vulgaris.
Tazarotene topical for acne vulgaris launches in United States
Tazarotene lotion 0.045% (Arazlo, Ortho Dermatologics) is officially launched in the U.S. following approval by the U.S. Food and Drug Administration in late 2019 for the treatment of acne vulgaris in patients 9 years and older.
Pembrolizumab approved by FDA for cSCC
The U.S. Food and Drug Administration has approved pembrolizumab for cutaneous squamous cell carcinoma whose disease has shown to not be curable by radiation or surgery.
Weekly Roundup: June 15-19
ICYMI, this week’s edition features articles about laser therapy for BCC, the growing interest in JAK-STAT inhibition, tips on how to sell your practice, apremilast for scalp pruritus, plus more.
Weekly Roundup: June 8-12
ICYMI, we've curated a list of all the stories we've published throughout the past week. Check out this article for more Dermatology Times content.
EMA accepts marketing application for tralokinumab
LEO Pharma will soon begin marketing its monoclonal antibody tralokinumab for atopic dermatitis with the announcement that the EMA has accepted the marketing authorization application for the drug.
Patient enrollment complete for tapinarof long-term safety study for psoriasis
Dermavant announces the enrollment completion for their long-term safety study investigating tapinarof in adults with plaque psoriasis as a part of the PSOARING 1 and PSOARING 2 phase 3 program.
2 Clarke Drive Cranbury, NJ 08512